Letter to the Editor: Rethinking Helicobacter pylori-associated gastroduodenal disease through a systemic immune lens

Abstract

For decades, Helicobacter pylori (H. pylori)-associated gastric diseases have been interpreted through a largely compartmentalized immunological lens, in which local mucosal inflammation is viewed as the primary driver of pathology and systemic immune responses are relegated to secondary or epiphenomenal roles. This framework, while useful, struggles to explain the remarkable heterogeneity of gastric outcomes arising from anatomically localized infection. Emerging human data increasingly suggest that gastric pathology may be embedded within broader systemic immune configurations, raising the possibility that circulating immune responses actively interact with local gastric processes rather than merely reflecting them. Within this context, recent work examining systemic cytokine dynamics before and after H. pylori eradication offers timely and provocative insights. The study by de Melo et al in the World Journal of Gastrointestinal Endoscopy demonstrates that gastritis and duodenal ulcer are associated with distinct systemic cytokine signatures and that bacterial eradication induces phenotype-specific immune recalibration rather than uniform immunological resolution. These findings challenge reductionist interpretations of gastric disease and support an integrated mucosal-systemic immune axis as a conceptual framework for understanding divergent gastric phenotypes. By reframing H. pylori-associated disease in this way, the study invites critical reassessment of long-standing assumptions regarding immune hierarchy and causality in gastric pathology. Recognizing systemic immunity as an active participant rather than a passive bystander may influence how immunological data are interpreted and how future studies are designed.

Key Words: Helicobacter pylori; Systemic immunity; Immune imprinting; Gastritis; Duodenal ulcer; Cytokine signatures

Core Tip: Emerging evidence suggests that Helicobacter pylori-associated gastroduodenal diseases are shaped not only by local mucosal inflammation but also by stable, phenotype-specific systemic immune states. Recent findings indicate that bacterial eradication induces distinct systemic immune recalibration in gastritis and duodenal ulcer, particularly involving regulatory pathways such as interleukin-10 signaling. Recognizing this systemic immune dimension may refine the interpretation of immunological data and inform future research beyond a purely gastric framework.

TO THE EDITOR

For decades, Helicobacter pylori (H. pylori)-associated diseases have been conceptualized primarily as localized disorders of the gastric mucosa, driven by site-specific inflammation and shaped by bacterial virulence, acid secretion, and mucosal defense mechanisms[1]. This framework has been instrumental in explaining classical clinical phenotypes such as chronic gastritis, duodenal ulcer, and gastric cancer, yet it remains insufficient to explain the striking heterogeneity of clinical outcomes observed in infected individuals. Increasingly, this limitation has prompted a reassessment of H. pylori infection as a condition embedded within broader, systemically coordinated immune responses rather than a purely local gastric disease[2,3].

Within this evolving conceptual landscape, the study by de Melo et al[4] in the World Journal of Gastrointestinal Endoscopy provides timely and provocative insight by interrogating systemic immune dynamics in patients with H. pylori-associated gastritis and duodenal ulcer before and after bacterial eradication. By longitudinally assessing circulating cytokine profiles, the authors demonstrate that eradication does not induce uniform immunological resolution but instead results in phenotype-specific systemic immune recalibration. These findings challenge reductionist interpretations of gastroduodenal disease and support a model in which local pathology reflects stable, systemically grounded immune programs.

SYSTEMIC INFLAMMATION AS A DEFINING FEATURE OF H. PYLORI INFECTION

Chronic H. pylori infection is invariably associated with persistent gastric inflammation; however, its contribution to sustained low-grade systemic inflammation has long been debated[1,2]. Circulating cytokines have often been regarded as secondary markers - epiphenomena reflecting mucosal immune activity without independent biological relevance. Accumulating evidence now challenges this view, suggesting that systemic immune responses to H. pylori are durable, phenotype-specific, and capable of influencing both gastric and extra-gastric disease trajectories[5,6].

The work of de Melo et al[4] directly addresses this gap by demonstrating distinct systemic cytokine signatures in patients with gastritis and duodenal ulcer, both before and after eradication. Importantly, eradication does not simply normalize systemic inflammation. Instead, it appears to unmask pre-existing immune states that evolve along divergent trajectories depending on the clinical phenotype. These findings imply that gastritis and duodenal ulcer are not interchangeable manifestations of a single inflammatory continuum, but rather reflect distinct systemic immune configurations.

Such observations align with broader paradigms in chronic infectious diseases, in which persistent antigenic stimulation leads to long-term immune imprinting that extends beyond the primary site of infection[2]. Within this framework, H. pylori may be more accurately conceptualized as a systemic immune modulator with localized gastric manifestations, rather than a strictly local pathogen with incidental systemic effects.

DIVERGENT CYTOKINE TRAJECTORIES AND SYSTEMIC IMMUNE IMPRINTING

A major strength of the study by de Melo et al[4] lies in its comparative, longitudinal design, which allows direct evaluation of systemic immune recalibration across two classical H. pylori-associated phenotypes. At baseline, patients with gastritis exhibited higher circulating levels of multiple pro-inflammatory cytokines, including interleukin (IL)-1α, IL-6, IL-12p70, IL-23, interferon-γ, and tumor necrosis factor α, compared with patients with duodenal ulcer. This pattern is consistent with a more globally activated systemic inflammatory state, mirroring the diffuse mucosal inflammation characteristic of gastritis[1,7].

Following eradication, cytokine levels declined in both groups; however, the qualitative nature of immune recalibration differed substantially. In gastritis, eradication was associated with broad suppression of pro-inflammatory mediators, consistent with partial resolution of chronic immune activation. In contrast, patients with duodenal ulcer demonstrated a more selective systemic response, characterized by relative preservation - or even augmentation - of regulatory signals, most notably IL-10[4].

These divergent trajectories strongly support the concept of systemic immune imprinting, whereby prolonged host-pathogen interaction establishes relatively stable immune states that are not fully reversed by bacterial clearance. Rather than representing transient inflammatory noise, systemic cytokine patterns may encode durable information about immune history, disease phenotype, and potentially long-term risk.

IL-10, IMMUNE PLASTICITY, AND REINTERPRETATION OF DUODENAL ULCER

Recent high-impact reviews emphasize the central role of immunoregulatory T-cell networks, particularly IL-10-mediated pathways, in shaping persistent and systemic immune states during H. pylori infection[8]. Among the most conceptually informative observations in the study is the opposing behavior of IL-10 following eradication. While IL-10 levels declined in gastritis, they increased in duodenal ulcer, suggesting a regulatory-skewed systemic immune profile in the latter. Traditionally, IL-10 has been interpreted as a simple anti-inflammatory mediator; however, contemporary immunology increasingly recognizes IL-10 expression as a hallmark of immune plasticity rather than as mere suppression.

Emerging evidence has identified IL-10-producing Th17 cells and IL-17-producing regulatory T cells as transitional immune populations that arise in chronic inflammatory settings, including persistent bacterial infection[9,10]. These populations reflect adaptive immune reprogramming aimed at balancing microbial control with tissue protection. In this context, the IL-10 dynamics reported by de Melo et al[4] may represent shifts in effector–regulatory balance rather than binary inflammatory states.

This perspective invites a re-evaluation of duodenal ulcer as an immunologically distinct phenotype. Beyond acid hypersecretion and localized mucosal injury, duodenal ulcer may reflect a regulatory-adaptive immune program that constrains excessive inflammation while permitting localized tissue damage under specific physiological conditions. Supporting this interpretation, previous studies have demonstrated distinct systemic and mucosal cytokine patterns in duodenal ulcer, including differential regulation of IL-17A, transforming growth factor-β, and IL-10, highlighting dissociation between local and systemic immune compartments[7,11].

SYSTEMIC IMMUNE STATES AND DISEASE BEYOND THE STOMACH

Recognition of phenotype-specific systemic immune imprinting has implications that extend beyond gastroduodenal pathology. A growing body of literature links H. pylori infection to extra-gastric inflammatory, metabolic, hematologic, and neoplastic conditions, implicating chronic low-grade systemic inflammation as a plausible mechanistic bridge[5,6]. The demonstration that eradication differentially reshapes systemic immunity depending on clinical phenotype adds important biological plausibility to these associations.

In patients with gastritis, eradication-associated attenuation of systemic inflammation may confer benefits extending beyond gastric symptom resolution. Conversely, in duodenal ulcer, reinforcement of regulatory pathways raises questions regarding long-term immune consequences, including potential trade-offs between inflammatory control and immune surveillance. These considerations underscore the importance of evaluating eradication therapy not solely as an antimicrobial intervention, but as an immunological perturbation whose systemic effects may vary across patient subgroups.

METHODOLOGICAL CONSIDERATIONS AND FUTURE DIRECTIONS

The longitudinal paired design employed by de Melo et al[4] represents a significant methodological strength, minimizing inter-individual variability and enabling direct assessment of immune recalibration over time. Although the cohort size is modest, the internal consistency and biological coherence of the findings support their conceptual significance.

Future studies integrating systemic cytokine profiling with mucosal immune phenotyping, cellular immune subsets, microbial virulence factors, and host genetic determinants will be essential to further delineate the mechanisms underlying systemic immune imprinting in H. pylori infection. Such integrative approaches may ultimately enable immune-informed patient stratification and a more nuanced interpretation of eradication outcomes.

CONCLUSIONS

By demonstrating phenotype-specific systemic immune recalibration following H. pylori eradication, de Melo et al[4] challenge the long-standing view of gastroduodenal diseases as purely local inflammatory disorders. Their findings support a model in which gastritis and duodenal ulcer represent distinct, systemically grounded immune phenotypes shaped by chronic host–pathogen interaction.

Recognizing systemic immunity as a stable, phenotype-defining component of H. pylori infection - rather than a transient epiphenomenon - may fundamentally reshape how these diseases are classified, studied, and ultimately managed. This systemic immune lens provides a more integrated framework for understanding the heterogeneity of H. pylori - associated pathology, with implications that extend well beyond the stomach.